Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation

N/A

Report date: 2023/10/26 16:56:33

Base Information

Drug NameLeber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation
Drug Alias Name莱伯氏先天性黑蒙症基因疗法AAV2-RPE65 VectorrAAV2-CB-hRPE65
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionRetinoid isomerohydrolase stimulantsGene transference
TargetsRetinoid isomerohydrolase
Therapy Area/IndicationsLeber Congenital Amaurosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesApplied Genetic
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesApplied Genetic Technologies Corp
Active IndicationsN/A
Inactive IndicationsLeber Congenital Amaurosis

Other Information

ATC CodeN/A
Related LinksN/A